DUSP9 and cardiac hypertrophy: To trace the potential molecular mechanisms behind this anti-hypertrophic action of DUSP9, we first highlighted the expression levels of MAPKs pathways, including p38, ERK1/2, and JNK, all are known to be important mediators responsible for the pathological cardiac hypertrophy 6, 8.